Ocular Therapeutix (OCUL) HCW @ Home summary

Regulatory and clinical development

• Ongoing collaborative discussions with the FDA regarding single pivotal trial approval for AXPAXLI in wet AMD, with robust phase III SOL-1 data meeting superiority endpoints and SPA requirements.

• SOL-1 demonstrated 74% of patients maintained vision at week 36 versus 56% for aflibercept, with a significant risk difference and strong safety profile.

• SOL-R and SOL-X extension trials continue to run efficiently, aiming to provide additional long-term outcome data and support broader label expansion.

• Post-hoc analyses highlight durability and disease control, with OCT endpoints showing stability within 30 microns at nine months for most patients.

• Diabetic retinopathy program (HELIOS-3) shows a single injection reduced vision-threatening complications to zero after one year in moderate to severe NPDR.

Market positioning and adoption

• AXPAXLI aims for the first and only superiority label among anti-VEGF agents, potentially protecting premium pricing and reducing step therapy barriers.

• Physicians value the ability to choose optimal therapy from day one, with the superiority label supporting broader adoption and payer support.

• Real-world adoption expected to exceed clinical trial performance due to easier patient selection and workflow integration.

• Commercial team and sales force are already established, leveraging experience from previous successful launches.

• No current plans for ex-U.S. partnerships; company is focused on standalone commercialization and global regulatory progress.

Safety, competition, and intellectual property

• Safety profile matches or exceeds current anti-VEGF therapies, with transparent reporting down to the patient level and no cases of endophthalmitis or vasculitis.

• Differentiation from competitors based on TKI potency, hydrogel delivery, and demonstrated superiority in disease control.

• IP portfolio extends to 2044, with ongoing filings to strengthen protection around manufacturing and methods.

• Manufacturing scale-up is supported by in-house capabilities and automation, with readiness for commercial launch.

• DEXTENZA retained to support commercial infrastructure and sales force expertise.